ClinicalTrials.gg
Active, not recruitingNCT06496178Updated Nov 12, 2026

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

A Phase 3 interventional study of Petosemtamab and Investigator's Choice in Head and Neck Squamous Cell Carcinoma, sponsored by Genmab. Active, not recruiting at 188 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Sponsor changed9 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
621
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
27th of 993
621 · median 41
Started
2024
with 64 others
Phase 3
71 of 1,099
12 open now
Primary completion
2028-02
later than 215 of 346 live
Registered
967th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 27th largest by enrollment of the 993 interventional ones that give a count, is one of 65 that started in 2024, is one of 71 in phase 3, reaches primary completion later than 215 of the 346 other live ones, and was the 967th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Read the detailed description

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease. HNSCC patients must have progressive disease (PD) on or after anti-PD-1 therapy and platinum-containing therapy. Patients treated with platinum-containing therapy only in the adjuvant setting, or in the context of multimodal therapy for locally advanced disease, should have PD within 6 months of the last dose of platinum-containing therapy.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • HNSCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ICF before initiation of any study procedures.
  • Age ≥ 18 years at signing of ICF.
  • Histologically previously confirmed HNSCC with evidence of or locally advanced disease not amenable to standard therapy with curative intent.
  • HNSCC participants progressed on or after therapy and platinum-containing therapy.
  • The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
  • A baseline new tumor sample unless the participant has an available tumor sample as an FFPE block with sufficient material.
  • as defined by v1.1 by radiologic methods.
  • PS of 0 or 1
  • ≥ 12 weeks, as per investigator
  • Adequate organ function (as per protocol)

Exclusion criteria

Exclusion Criteria:

  • Central nervous system that are untreated or symptomatic, or require radiation, surgery, or continued therapy to control symptoms within 14 days prior to randomization.
  • Known
  • Any systemic anticancer therapy within 4 weeks prior to randomization.
  • Major surgery within 3 weeks or palliative radiotherapy within 2 weeks prior to randomization.
  • Persistent Grade >1 toxicities related to prior antineoplastic therapies
  • History of reaction to any of the of treatment required for this study.
  • Unstable angina; history of congestive heart failure of Class II-IV (NYHA) criteria, or serious cardiac arrhythmia requiring treatment or history of myocardial infarction within 6 months of study entry
  • History of prior with the exception of localized cancer with curative resection (e.g. cervical intraepithelial neoplasia or nonmelanoma skin cancer)
  • Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy
  • Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders
  • Participants with known infectious diseases (as per protocol)
  • Pregnant or breastfeeding participants
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
621 participants (actual)

Study arms

  • Experimental
    MCLA-158

    Drug: Petosemtamab

  • Active comparator
    Investigator's Choice

    Drug: Investigator's Choice

Interventions

  • MCLA-158

  • DrugInvestigator's Choice

    Cetuximab

  • DrugInvestigator's Choice

    Methotrexate

  • DrugInvestigator's Choice

    Docetaxel

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review

    ORR was defined as the proportion of participants in the analysis population who had a Complete Response or Partial Response based per RECIST v1.1 with confirmation.

    Time frame: Up to approximately 2 years

  2. Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review

    PFS was defined as the time from randomization to the first documented disease progression per RECIST v1.1 or death due to any cause.

    Time frame: Up to approximately 2 years

  3. Duration of Response (DOR) as Assessed by Blinded Independent Central Review

    For participants with a confirmed CR or PR per RECIST v1.1, DOR was defined as the time from the date of first documented response of CR or PR per RECIST v1.1 to the date of first documented progression or death due to underlying cancer.

    Time frame: Up to approximately 2 years

  4. Objective Response Rate (ORR) as Assessed by Investigator Review

    ORR was defined as the proportion of participants in the analysis population who had a Complete Response or Partial Response based per RECIST v1.1 with confirmation.

    Time frame: Up to approximately 2 years

  5. Progression Free Survival (PFS) as Assessed by Investigator Review

    PFS was defined as the time from randomization to the first documented disease progression per RECIST v1.1 or death due to any cause.

    Time frame: Up to approximately 2 years

  6. Duration of Response (DOR) as Assessed by Investigator Review

    For participants with a confirmed CR or PR per RECIST v1.1, DOR was defined as the time from the date of the first documented response of CR or PR per RECIST v1.1 to the date of first documented progression or death due to underlying cancer.

    Time frame: Up to approximately 2 years

  7. Time to Response (TTR) as Assessed by Blinded Independent Central Review

    For participants with a confirmed CR or PR per RECIST v1.1, TTR was defined as the time from randomization to the first documented response per RECIST v1.1.

    Time frame: Up to approximately 2 years

  8. Time to Response (TTR) as Assessed by Investigator Review

    For participants with a confirmed CR or PR per RECIST v1.1, TTR was defined as the time from randomization to the first documented response per RECIST v1.1.

    Time frame: Up to approximately 2 years

  9. Clinical Benefit Rate (CBR) as Assessed by Blinded Independent Central Review

    CBR was defined as the proportion of participants with a confirmed CR or PR, or SD lasting 16 weeks for longer per RECIST v1.1

    Time frame: Up to approximately 2 years

  10. Clinical Benefit Rate (CBR) as Assessed by Investigator Review

    CBR was defined as the proportion of participants with a confirmed CR or PR, or SD lasting 16 weeks for longer per RECIST v1.1

    Time frame: Up to approximately 2 years

  11. Number of Participants who Experienced At Least One Treatment Emergent Adverse Event (TEAE)

    An AE means any untoward medical occurrence associated with use of a drug in humans, whether or not considered drug related. The term TEAE covers any unfavorable and unintended sign, symptom, syndrome, or illness that develops or worsens during the period of observation after the first treatment administration in the clinical study. The number of all participants who experienced at least one TEAE is presented.

    Time frame: Up to 30 days post-last dose

  12. Number of Participants who Experienced At Least One Serious TEAE

    An AE means any untoward medical occurrence associated with use of a drug in humans, whether or not considered drug related. The term TEAE covers any unfavorable and unintended sign, symptom, syndrome, or illness that develops or worsens during the period of observation after the first treatment administration in the clinical study. The number of all participants who experienced at least one serious TEAE is presented.

    Time frame: Up to 30 days post-last dose

  13. Number of Participants who Discontinued Study Treatment Due to TEAEs

    An AE means any untoward medical occurrence associated with use of a drug in humans, whether or not considered drug related. The term TEAE covers any unfavorable and unintended sign, symptom, syndrome, or illness that develops or worsens during the period of observation after the first treatment administration in the clinical study. The number of all participants who discontinued study treatment due to TEAEs is presented.

    Time frame: Up to 30 days post-last dose

  14. Number of Participants who had Dose Modification Due to TEAEs

    An AE means any untoward medical occurrence associated with use of a drug in humans, whether or not considered drug related. The term TEAE covers any unfavorable and unintended sign, symptom, syndrome, or illness that develops or worsens during the period of observation after the first treatment administration in the clinical study. The number of all participants who had dose modification due to TEAEs is presented.

    Time frame: Up to 30 days post-last dose

  15. Pharmacokinetic parameters

    Clearance of plasma and central volume of distribution based on population PK model

    Time frame: Up to first 6 cycles

07

Study locations

188 sites
  • Site 160
    Mobile, Alabama 36608, United States
  • Site 102
    Prescott, Arizona 86301, United States
  • Site 125
    Scottsdale, Arizona 85054, United States
  • Site 82
    Duarte, California 91010, United States
  • Site 25
    La Jolla, California 92037, United States
  • Site 173
    Orange, California 92868, United States
  • Site 28
    Palo Alto, California 94304, United States
  • Site 127
    Sacramento, California 95817, United States
  • Site 46
    San Francisco, California 94158, United States
  • Site 130
    Lone Tree, Colorado 80124, United States
  • Site 104
    Washington D.C., District of Columbia 20010, United States
  • Site 12
    Fort Myers, Florida 33901, United States
  • Site 123
    Jacksonville, Florida 32224, United States
  • Site 9
    Orlando, Florida 32827, United States
  • Site 138
    Tampa, Florida 33612, United States
  • Site 187
    Atlanta, Georgia 30322, United States
  • Site 152
    Chicago, Illinois 60607, United States
  • Site 213
    Chicago, Illinois 60611, United States
  • Site 68
    Chicago, Illinois 60637, United States
  • Site 31
    Indianapolis, Indiana 46202, United States
  • Site 8
    Louisville, Kentucky 40202, United States
  • Site 40
    Baton Rouge, Louisiana 70809, United States
  • Site 100
    New Orleans, Louisiana 70121, United States
  • Site 153
    Columbia, Maryland 21044, United States
  • Site 77
    Boston, Massachusetts 02215, United States
  • Site 103
    Ann Arbor, Michigan 48109, United States
  • Site 5
    Detroit, Michigan 48201, United States
  • Site 49
    Maple Grove, Minnesota 55369, United States
  • Site 124
    Rochester, Minnesota 55905, United States
  • Site 18
    St Louis, Missouri 63110, United States
  • Site 15
    Albuquerque, New Mexico 87131, United States
  • Site 24
    New York, New York 10029, United States
  • Site 214
    The Bronx, New York 10461, United States
  • Site 98
    Chapel Hill, North Carolina 27514, United States
  • Site 122
    Durham, North Carolina 27710, United States
  • Site 23
    Cincinnati, Ohio 45219, United States
  • Site 218
    Cleveland, Ohio 44106, United States
  • Site 87
    Cleveland, Ohio 44195, United States
  • Site 32
    Columbus, Ohio 43210, United States
  • Site 26
    Portland, Oregon 97213, United States
  • Site 151
    Bensalem, Pennsylvania 19020, United States
  • Site 158
    Philadelphia, Pennsylvania 19107, United States
  • Site 50
    Charleston, South Carolina 29425, United States
  • Site 60
    Chattanooga, Tennessee 37404, United States
  • Site 54
    Memphis, Tennessee 38103, United States
  • Site 59
    Nashville, Tennessee 37203, United States
  • Site 67
    Nashville, Tennessee 37232, United States
  • Site 55
    Denison, Texas 75020, United States
  • Site 34
    El Paso, Texas 79915, United States
  • Site 51
    Houston, Texas 77030, United States
  • Site 7
    Houston, Texas 77030, United States
  • Site 94
    Pearland, Texas 77584, United States
  • Site 4
    Salt Lake City, Utah 84112, United States
  • Site 10
    Blacksburg, Virginia 24060, United States
  • Site 22
    Charlottesville, Virginia 22908, United States
  • Site 156
    Winchester, Virginia 22601, United States
  • Site 163
    Seattle, Washington 98109, United States
  • Site 6
    Spokane, Washington 99202, United States
  • Site 216
    Madison, Wisconsin 53705, United States
  • Site 58
    Caba, C1280AEB, Argentina
  • Site 45
    Córdoba, X5008HHW, Argentina
  • Site 110
    Rosario, S2000KZE, Argentina
  • Site 57
    Viedma, 8500, Argentina
  • Site 3
    Darlinghurst, 2010, Australia
  • Site 170
    Herston, 4060, Australia
  • Site 38
    Melbourne, 3000, Australia
  • Site 30
    Nedlands, 6009, Australia
  • Site 11
    Saint Leonards, 2065, Australia
  • Site 73
    Sydney, 2050, Australia
  • Site 56
    Brussels, 1200, Belgium
  • Site 92
    Ghent, 9000, Belgium
  • Site 72
    Leuven, 3000, Belgium
  • Site 108
    Liège, 4000, Belgium
  • Site 69
    Namur, 5000, Belgium
  • Site 154
    Brasília, 70390-140, Brazil
  • Site 145
    Porto Alegre, 90110-270, Brazil
  • Site 150
    Porto Alegre, 90610-000, Brazil
  • Site 148
    Rio de Janeiro, 22281-100, Brazil
  • Site 147
    São Paulo, 01509-900, Brazil
  • Site 144
    São Paulo, 04538-132, Brazil
  • Site 172
    Montreal, H2X 0A9, Canada
  • Site 196
    Toronto, M4N 3M5, Canada
  • Site 16
    Providencia, 7500859, Chile
  • Site 20
    Recoleta, 8420000, Chile
  • Site 27
    Santiago, 7500921, Chile
  • Site 21
    Santiago, 7560908, Chile
  • Site 201
    Olomouc, 779 00, Czechia
  • Site 105
    Bordeaux, 33075, France
  • Site 211
    Brest, 29200, France
  • Site 162
    Le Mans, 72000, France
  • Site 149
    Lille, 59000, France
  • Site 118
    Lyon, 69373, France
  • Site 115
    Marseille, 13005, France
  • Site 106
    Montpellier, 34298, France
  • Site 169
    Nice, 06189, France
  • Site 114
    Paris, 75005, France
  • Site 167
    Paris, 75013, France
  • Site 136
    Poitiers, 86000, France
  • Site 141
    Rennes, 35042, France
  • Site 107
    Rouen, 76038, France

Showing the first 100 of 188 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Machiels JP, Fayette J, Haddad R, Adkins D, Gillison M, Harrington KJ, Kim SB, Le Tourneau C, Psyrri A, Rosenberg A, Siu LL, Tahara M, William WN Jr, Ford J, Jauhari S, Pyle R, Shen YM, Yao D, Zohren F, Vokes E. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13. PubMed 40511820 ↗
09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Feb 2028, 44 months after the start.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's planned 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 11, 2024
StartActual
Jun 25, 2024
Primary completionEst.
Feb 2028
CompletionEst.
Mar 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites removed
Show 9 removed
  • Site 207 · Atlanta, United States
  • Site 193 · CABA, Argentina
  • Site 96 · Athens, Greece
  • Site 126 · Rio, Greece
  • Site 86 · Hackensack, United States
  • Site 146 · Recife, Brazil
  • Site 84 · Giessen, Germany
  • Site 76 · Amsterdam, Netherlands
  • Site 182 · Coimbra, Portugal
across 3 updates, Sep 25, 2026 – Nov 12, 2026
Sponsor
Merus B.V.→Genmab
Nov 2, 2026
Show all 4 updates
  1. Nov 12, 2026
    5 sites removed
    Show 5 removed
    • Site 86 · Hackensack, United States
    • Site 146 · Recife, Brazil
    • Site 84 · Giessen, Germany
    • Site 76 · Amsterdam, Netherlands
    • Site 182 · Coimbra, Portugal
    + 1 other change: verification date
  2. Nov 2, 2026
    Sponsor Merus B.V.→Genmab
    + 3 other changes: identifiers, verification date and contact details
  3. Oct 19, 2026
    1 site removed
    Show 1 removed
    • Site 126 · Rio, Greece
  4. Sep 25, 2026
    3 sites removed
    Show 3 removed
    • Site 207 · Atlanta, United States
    • Site 193 · CABA, Argentina
    • Site 96 · Athens, Greece

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06496178
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Jun 25, 2024
Primary completion
Feb 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Study Official
study director · Genmab

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Petosemtamab

Start the discussion